AU590578B2 - Treatment of non-ulcer dyspepsia with bismuth salts - Google Patents

Treatment of non-ulcer dyspepsia with bismuth salts

Info

Publication number
AU590578B2
AU590578B2 AU59026/86A AU5902686A AU590578B2 AU 590578 B2 AU590578 B2 AU 590578B2 AU 59026/86 A AU59026/86 A AU 59026/86A AU 5902686 A AU5902686 A AU 5902686A AU 590578 B2 AU590578 B2 AU 590578B2
Authority
AU
Australia
Prior art keywords
ulcer dyspepsia
antibiotics
bismuth salt
antibiotic
amoxycillin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU59026/86A
Other languages
English (en)
Other versions
AU5902686A (en
Inventor
Thomas Julius Borody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3771057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU590578(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of AU5902686A publication Critical patent/AU5902686A/en
Application granted granted Critical
Publication of AU590578B2 publication Critical patent/AU590578B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU59026/86A 1985-04-18 1986-04-18 Treatment of non-ulcer dyspepsia with bismuth salts Expired AU590578B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPH019885 1985-04-18
AUPH0198 1985-04-18

Publications (2)

Publication Number Publication Date
AU5902686A AU5902686A (en) 1986-11-05
AU590578B2 true AU590578B2 (en) 1989-11-09

Family

ID=3771057

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59026/86A Expired AU590578B2 (en) 1985-04-18 1986-04-18 Treatment of non-ulcer dyspepsia with bismuth salts

Country Status (5)

Country Link
EP (1) EP0222834A4 (fr)
JP (1) JPS62502967A (fr)
AU (1) AU590578B2 (fr)
SG (1) SG72632A1 (fr)
WO (1) WO1986005981A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU621285B2 (en) * 1987-03-09 1992-03-12 Procter & Gamble Company, The Compositions and methods for treating gastrointestinal disorders

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318144T1 (de) * 1985-06-13 2006-03-15 Barry James Marshall Pharmazeutische zusammensetzung zur behandlung gastrointestinaler beschwerden, die wismut und ein antimikrobielles mittel enthält
ATE81011T1 (de) * 1987-03-09 1992-10-15 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
AU623868B2 (en) * 1987-10-12 1992-05-28 Capability Services Pty. Limited Improved method for treatment of gastrointestinal disorders
JP2733849B2 (ja) * 1987-10-12 1998-03-30 ボロディー，ソーマス・ユリウス 胃腸障害治療のための改良された方法
US4935406A (en) * 1988-09-20 1990-06-19 Marion Laboratories, Inc. Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders
EP0375068A1 (fr) * 1988-12-23 1990-06-27 Gist-Brocades N.V. Associations de composés de bismuth et de tétracyclines
EP0403048A3 (fr) * 1989-06-14 1991-01-30 Warner-Lambert Company Un modèle de structure de système craniomandibulaire humain
FI910088A (fi) * 1990-01-09 1991-07-10 Gist Brocades Nv Oral farmaceutisk komposition.
YU45590A (sh) * 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
US5192752A (en) * 1991-01-14 1993-03-09 The Procter & Gamble Company Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
EP0624373B1 (fr) * 1993-05-11 1999-09-08 Spirig Ag Pharmazeutische Präparate Composition pharmaceutique contenant du bismuth et de l'amoxycillin et son utilisation
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US6902738B2 (en) 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
PE48297A1 (es) * 1995-05-09 1998-02-04 Procter & Gamble Metodos y composiciones para la prevencion y el tratamiento de desordenes gastrointestinales
US5702729A (en) * 1995-12-07 1997-12-30 The Procter & Gamble Company Methods for the prevention and treatment of gastrointestinal disorders caused or mediated by algae or cyanobacteria
US6051604A (en) * 1995-12-07 2000-04-18 The Proctor & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
US5744168A (en) * 1995-12-07 1998-04-28 The Procter & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
BR112013014827A2 (pt) 2010-12-13 2016-10-04 Antony Wettstein formulações gástricas e colônicas e métodos para produzir e usar as mesmas
WO2014016671A2 (fr) 2012-07-27 2014-01-30 Redhill Biopharma Ltd. Formulations et procédés de fabrication de formulations destinées à être utilisées en évacuation du côlon

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2053002A1 (en) * 1969-06-21 1971-04-16 Clin Midy Bismuth slats of alpha methiminobenzyl - penicillin
AU440535B2 (en) * 1969-12-18 1973-09-17 Export Drugs Company Antacid compositions
AU563692B2 (en) * 1981-09-22 1987-07-16 Brocades Pharma B.V. Bismuth containing composition and method for the preparationthereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6063965A (en) * 1965-06-25 1967-01-05 Morton W. Scott Belayed acting compositions
US3621094A (en) * 1968-04-05 1971-11-16 Smith Kline French Lab Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts
GB1269987A (en) * 1968-04-18 1972-04-12 Garland Richard Brown Antacid composition
GB1220819A (en) * 1968-04-24 1971-01-27 Mar Pha Soc D Etude Et D Expl Improved bismuth salt
US4153685A (en) * 1968-11-23 1979-05-08 Schering Corporation Bismuth complex preparations
FR2029402A1 (fr) * 1969-01-28 1970-10-23 Breive Et Son Jib Labo Produit destiné à régulariser la digestion dans l'estomac et l'intestin
FR2073254A2 (en) * 1969-12-04 1971-10-01 Dausse Laboratoire Gum guar stabilised suspensions - of insoluble medicaments for treati gastrointestinal disorders
FR2092636A1 (en) * 1970-06-03 1972-01-28 Griffon Henri Dried yeast - bismuth subnitrate compositions - for gastrointestinal disorders
ZA74385B (en) * 1974-01-18 1975-08-27 Gist Brocades Nv Pharmaceutical compositions
HU179474B (en) * 1978-02-24 1982-10-28 Laszlo Gyarmati Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material
US4588589A (en) * 1983-10-13 1986-05-13 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof
EP0206626B2 (fr) * 1985-06-13 2002-05-22 Barry James Dr. Marshall Utilisation de bismuth pour la fabrication d'un médicament destiné au traitement des désordres gastrointestinaux dûs à Campylobacter polyridis
ATE318144T1 (de) * 1985-06-13 2006-03-15 Barry James Marshall Pharmazeutische zusammensetzung zur behandlung gastrointestinaler beschwerden, die wismut und ein antimikrobielles mittel enthält

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2053002A1 (en) * 1969-06-21 1971-04-16 Clin Midy Bismuth slats of alpha methiminobenzyl - penicillin
AU440535B2 (en) * 1969-12-18 1973-09-17 Export Drugs Company Antacid compositions
AU563692B2 (en) * 1981-09-22 1987-07-16 Brocades Pharma B.V. Bismuth containing composition and method for the preparationthereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU621285B2 (en) * 1987-03-09 1992-03-12 Procter & Gamble Company, The Compositions and methods for treating gastrointestinal disorders

Also Published As

Publication number Publication date
AU5902686A (en) 1986-11-05
JPS62502967A (ja) 1987-11-26
EP0222834A1 (fr) 1987-05-27
SG72632A1 (en) 2000-05-23
EP0222834A4 (fr) 1989-10-04
WO1986005981A1 (fr) 1986-10-23

Similar Documents

Publication Publication Date Title
AU590578B2 (en) Treatment of non-ulcer dyspepsia with bismuth salts
US5256684A (en) Methods and compositions for the treatment of gastrointestinal disorders
CA1277232C (fr) Methodes et composes pour le traitement des troubles gastro-intestinaux
US5601848A (en) Methods for the treatment of gastrointestinal disorders
KR960016582B1 (ko) 위장장해의 치료 및 예방용 약제학적 조성물
US5629297A (en) Medicament for treating gastrointestinal disorders
CA2344308C (fr) Taurolidine et/ou taurultam destines a la lutte contre les ulceres ou les gastrites d'origine infectieuse
EP0544760B1 (fr) Compositions pharmaceutiques contenant du 5-difluoromethoxy-2- (3,4-dimethoxy-2-pyridyle) methylsulfinyle]benzimidazole et un agent anti-helicobacter pour le traitement des troubles gastro-intestinaux
Hewitt The penicillins: a review of strategy and tactics
EP0219912B1 (fr) L'utilisation du nitrofurantoine pour le traitement et la prophylaxie des maladies gastro-intestinales
Labenz et al. High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease
KR20010024050A (ko) 항균제
EP0591446B1 (fr) Procede de traitement des gastrites a helicobacter pylori
Glupczynski In vitro susceptibility of Helicobacter pylori to antibiotics and bismuth salts and the importance of acquired resistance to antibiotics in treatment failures of H. pylori infection
EP0865286B1 (fr) Compositions destinees a la prevention et au traitement de troubles gastro-intestinaux et comprenant du bismuth ainsi qu'un ou plusieurs agents antimicrobiens
WO1994027579A1 (fr) Composition pour le traitement d'ulceres
RU2187318C2 (ru) Способ лечения хронического гастрита и язвенной болезни двенадцатиперстной кишки
RU2076708C1 (ru) Фармацевтическая композиция и способ лечения и профилактики гастроэнтерологических заболеваний
Byakod et al. Clinical evaluation of lincomycin, a new antibiotic
JPH0920668A (ja) 微好気性グラム陰性桿菌ヘリコバクター・ピロリの抗菌剤
O’Morain How to eradicate Helicobacter pylori and prevent reinfection
JPH11246401A (ja) ヘリコバクターピロリ感染症治療剤